Trial Profile
A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-Duodenectomy for Resection of Pancreatic Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Pharmacokinetics
- 31 Aug 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 27 May 2010 Actual initiation date (Nov 2009) added as reported by ClinicalTrials.gov.
- 27 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.